Submit Content
Get the latest delivered to your inbox
Privacy Policy

Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.

 

Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.

    Novartis Supports EDCTP’s Career Development Programme, Focusing on Maternal and Child Health Image

    POSTED 

    11-26-19

    Novartis Supports EDCTP’s Career Development Programme, Focusing on Maternal and Child Health

    Novartis will support the career development programme of the European & Developing Countries Clinical Trials Partnership (EDCTP). The programme aims to provide early- to mid-career researchers in sub-Saharan Africa with an opportunity to train and develop their clinical research skills.

    ...
    Novartis annonce une nouvelle stratégie pour fournir des traitements innovants à plus de patients en Afrique subsaharienne Image

    POSTED 

    11-13-19

    Novartis annonce une nouvelle stratégie pour fournir des traitements innovants à plus de patients en Afrique subsaharienne

    Novartis a annoncé aujourd’hui une nouvelle stratégie visant à élargir l’accès des patients et la disponibilité de sa gamme de médicaments en Afrique subsaharienne, qui regroupe la plus vaste population au monde de patients mal desservis. Novartis souhaite également être le partenaire de choix de...

    Novartis Announces New Strategy to Provide Innovative Medicines to More Patients in Sub-Saharan Africa Image

    POSTED 

    11-13-19

    Novartis Announces New Strategy to Provide Innovative Medicines to More Patients in Sub-Saharan Africa

    Novartis announced today a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest underserved patient population in the world. Novartis also aspires to be the partner of choice for governments and NGOs to stre...

    Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global Medicines Company Novartis Image

    POSTED 

    11-11-19

    Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global Medicines Company Novartis

    Today, the Government of Ghana announced the availability of hydroxyurea for the treatment of people with sickle cell disease (SCD), marking the official launch of a first of its kind public-private partnership to improve the diagnosis and accelerate treatment for people with SCD. The launch foll...

    Uncovering Sickle Cell Disease Image

    POSTED 

    06-20-19

    Uncovering Sickle Cell Disease

    Every day, people endure the painful and life-threatening symptoms of sickle cell disease in the shadows because of fear, stigma,and isolation.1,2,3

    Today, on World Sickle Cell Day, Novartis is helping raise awareness on the disease and its complications by sharing a collection ...

    Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug Image

    POSTED 

    04-15-19

    Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug

    The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West an...

    Novartis Releases Novartis in Society 2018 Report Image

    POSTED 

    02-04-19

    Novartis Releases Novartis in Society 2018 Report

    For the sixth consecutive year, Novartis is publishing an annual Novartis in Society report (formerly our Corporate Responsibility Report).

    The report is divided into four chapters based on our corporate responsibility (CR) material clusters and the global health and CR strategic prioritie...

    Novartis Releases 2017 Corporate Responsibility Report Image

    POSTED 

    01-25-18

    Novartis Releases 2017 Corporate Responsibility Report

    For the fifth consecutive year, Novartis is publishing an annual Corporate Responsibility (CR) Report.  The report is divided into four chapters based on our CR material clusters: access to healthcare, innovation, patient health and safety and ethical business practices.  Each chapter provides re...

    Novartis Releases 2016 Corporate Responsibility Performance Report Image

    POSTED 

    01-25-17

    Novartis Releases 2016 Corporate Responsibility Performance Report

    Novartis has published its Corporate Responsibility (CR) Performance Report for 2016. This year’s report provides even more context on the company’s CR performance, as well as views and comments on trends and challenges within the healthcare industry. 

    This is the fourth consecutive year N...

    Novartis Releases 2015 Corporate Responsibility Performance Report Image

    POSTED 

    01-27-16

    Novartis Releases 2015 Corporate Responsibility Performance Report

    Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthc...

    Novartis Logo

    Novartis

    Novartis

    Join today and get the latest delivered to your inbox